Dr. KC is an experienced chemist who has over two decades of experience in drug discovery and CMC with a proven track record of successfully leading medicinal chemistry and CMC projects in every stage of drug discovery and development processes spanning from HTS to process validation and cGMP manufacturing of registration/PPQ batches of drug substance to support approval and post approval commercialization. Previously, Dr. KC was the Vice President of Chemistry at Samumed LLC where he played a key role in discovering and advancing seven NCEs to the clinic, and led CMC operational and strategic activities that included process development and cGMP manufacturing of drug substances to support phase 1-3 clinical trials of seven NCEs for eight different indications. At Samumed, Dr. KC successfully oversaw the design and execution of PPQ enabling multifunctional projects and PPQ campaign of Lorecivivint drug substance. Prior to Samumed, Dr. KC was the Associate Director of Chemistry at Avanir Pharmaceuticals, where he led a team of medicinal chemists working in drug discovery of various therapeutic areas. His team at Avanir discovered two NCEs that entered into the clinic and delivered two projects that were successfully out-licensed to Novartis and AstraZeneca. Dr. KC is an author of 21 peer reviewed scientific publications and inventor on more than 400 pending and issued patents. Dr. KC received his Ph.D. in Medicinal Chemistry from the University of Regensburg, Germany and M.Sc. in Organic Chemistry from Tribhuvan University, Nepal.